Tenaya Therapeutics (TNYA) Proxy filing summary

Executive summary

• Special meeting set for Dec. 9, 2026; the sole proposal seeks authority for a discretionary 1-for-10 to 1-for-25 reverse split.

• Nasdaq granted a compliance period through Jan. 25, 2027, requiring a closing bid of at least $1.00 for 10 consecutive business days.

Voting matters and shareholder proposals

• Board unanimously approved the proposal on Sept. 17, 2026, and recommends FOR; approval requires votes cast FOR to exceed votes cast AGAINST.

• Record date is Oct. 19, 2026; 227,928,240 common shares were outstanding, with one vote per share.

• If approved, the board may choose a ratio within the 1-for-10 to 1-for-25 range or abandon implementation before the one-year anniversary of the meeting.

Board of directors and corporate governance

• The board retains sole discretion over whether and when to implement the split and its ratio; no further stockholder action is required to implement or abandon it.